UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies

Therapeutic Advances in Medical Oncology, 2018-01, Vol.10, p.1758835918786658-1758835918786658

2018

Volltextzugriff (PDF)

Challenging the recalcitrant disease—developing molecularly driven treatments for small cell lung cancer

European journal of cancer (1990), 2019-09, Vol.119, p.132-150

2019

Volltextzugriff (PDF)

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

Clinical cancer research, 2020-09, Vol.26 (18), p.4805-4813

2020

Volltextzugriff (PDF)

Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy

PloS one, 2022-07, Vol.17 (7), p.e0270950-e0270950

2022

Volltextzugriff (PDF)

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic

The lancet oncology, 2020-07, Vol.21 (7), p.889-891

2020

Volltextzugriff (PDF)

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Journal of clinical oncology, 2024-06

2024

Volltextzugriff (PDF)

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers

Molecular cancer therapeutics, 2019-08, Vol.18 (8), p.1396-1404

2019

Volltextzugriff (PDF)

Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov

Cancer medicine (Malden, MA), 2021-11, Vol.10 (22), p.7943-7957

2021

Volltextzugriff (PDF)

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets

Molecular oncology, 2023-02, Vol.17 (2), p.230-237

2023

Volltextzugriff (PDF)

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease

BMC cancer, 2020-12, Vol.20 (1), p.1210-1210, Article 1210

2020

Volltextzugriff (PDF)

Contrast Clearance Analysis (CCA) to Assess Viable Tumour following Stereotactic Radiosurgery (SRS) to Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC)

Cancers, 2024-03, Vol.16 (6), p.1218

2024

Volltextzugriff (PDF)

Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center

Cancers, 2019-10, Vol.11 (10), p.1558

2019

Volltextzugriff (PDF)

Sitravatinib and Acquired Immune Checkpoint Inhibitor Resistance: A Gem for the Future?

Journal of thoracic oncology, 2023-07, Vol.18 (7), p.830-833

2023

Volltextzugriff (PDF)

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma

PloS one, 2019-11, Vol.14 (11), p.e0225509

2019

Volltextzugriff (PDF)

Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease

BMC cancer, 2021-03, Vol.21 (1), p.245-245, Article 245

2021

Volltextzugriff (PDF)

Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs

Research involvement and engagement, 2024-06, Vol.10 (1), p.63-9, Article 63

2024

Volltextzugriff (PDF)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Journal for immunotherapy of cancer, 2022-06, Vol.10 (6), p.e004495

2022

Volltextzugriff (PDF)

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

PloS one, 2017-10, Vol.12 (10), p.e0186106-e0186106

2017

Volltextzugriff (PDF)

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)

BMJ open, 2021-09, Vol.11 (9), p.e049217-e049217

2021

Volltextzugriff (PDF)

A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients

Cancer reports, 2024-06, Vol.7 (6), p.e2083-n/a

2024

Volltextzugriff (PDF)

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy

Journal of Immunotherapy and Precision Oncology, 2021-11, Vol.4 (4), p.189-195

2021

Volltextzugriff (PDF)

Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs

Journal of Immunotherapy and Precision Oncology, 2019-05, Vol.2 (2), p.23-35

2019

Volltextzugriff (PDF)

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications

Frontiers in medicine, 2021-11, Vol.8, p.764563-764563

2021

Volltextzugriff (PDF)

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience

Cancer treatment and research communications, 2020, Vol.25, p.100261-100261, Article 100261

2020

Volltextzugriff (PDF)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab

Journal for immunotherapy of cancer, 2020-03, Vol.8 (1), p.e000713

2020

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(127)

Sprache

Englisch
(126)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies

Challenging the recalcitrant disease—developing molecularly driven treatments for small cell lung cancer

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers

Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease

Contrast Clearance Analysis (CCA) to Assess Viable Tumour following Stereotactic Radiosurgery (SRS) to Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC)

Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center

Sitravatinib and Acquired Immune Checkpoint Inhibitor Resistance: A Gem for the Future?

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma

Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease

Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designs

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)

A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy

Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab

Suchergebnisse filtern